View Federal Register notices of proposed exclusive licenses. Clicking on the "View" links will display the Federal Register Notice in a new tab. You can also search directly on the Federal Register site.
Interested parties should notify this office in writing by September 11, 1995. Respondents will then be given an additional sixty (60) days for filing a formal proposal.
In view of the high priority for developing and commercializing testosterone bucyclate, all proposals must be received no later than September 5, 1995 for priority consideration.
In view of the important priority of developing new agents for the treatment or prevention of cancer, interested parties should notify this office in writing no later than June 25, 1995. Respondents will then be provided an additional 60 days for the filing of formal proposals.
In view of the important priority of developing new drugs for the treatment or prevention of cancer, interested parties should notify this office in writing no later than June 26, 1995. Respondents will then be provided an additional 60 days for the filing of formal proposals.
In view of the high priority for developing new drugs for the treatment of HIV infection, all proposals must be received by no later than May 30, 1995.
Capability statements/CRADA proposals must be received by NIH on or before May 22, 1995. There is no [[Page 14956]] deadline by which license applications must be received.
(a) When the MATERIAL becomes generally available from third parties, for example, through reagent catalogs or public depositories, or (b) on completion of the RECIPIENT's current research with the MATERIAL, or (c) on thirty (30) days written notice by either party to the other, or (d) on the date specified in an implementing letter, provided that:
Interested parties should notify this office in writing no later than sixty (60) days from the date of this announcement in the Federal Register. Respondents will then be provided an additional, sixty (60) days for the filing of formal proposals.
